Clinical Trials Sponsored by EnGene, Inc.

Total 36927 results

BeiGene

Recruiting

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

B-cell Malignancies

China, Italy, United States, Spain, United Kingdom, Poland, Czechia, Netherlands, Greece, France, Sweden, Korea, Republic of, Turkey
BeiGene

Recruiting

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

Urothelial Carcinoma

China
BeiGene

Recruiting

Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors

Locally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2

Australia, United States, Spain, France, Italy, Korea, Republic of, Poland
Celgene

Recruiting

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

Spain, Italy, Germany, Austria, France, Greece, Netherlands
Celgene

Recruiting

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)

Multiple Myeloma

United States, France, Germany, Spain, United Kingdom, Italy
Celgene

Completed

A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States
BeiGene

Completed

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Relapsed/Refractory Diffuse Large B-Cell Lymphoma

China
BeiGene

Completed

BGB-DXP604 Alone and in Combination With BGB-DXP593 in Healthy Participants

Healthy

Australia
BeiGene

Active, not recruiting

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Locally Advanced and Metastatic Solid Tumors

China, Taiwan, United States, Australia
BeiGene

Completed

A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

Advanced Hepatocellular Carcinoma

China, Taiwan
BeiGene

Enrolling by invitation

Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies

Advanced Malignancies

China, Taiwan, Korea, Republic of, Turkey
Celgene

Completed

A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients

Leukemia, Myeloid, Acute

Korea, Republic of, Australia
BeiGene

Completed

Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors

Triple Negative Breast Cancer | Advanced High-grade Ovarian Cancer

China
Celgene

Completed

A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

Neoplasms

United States, France, Italy, Poland, Spain, United Kingdom
Celgene

Active, not recruiting

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

Spain, Canada, United States
BeiGene

Active, not recruiting

Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma

Gastric, or Gastroesophageal Junction Adenocarcinoma

United States, China, Spain, Korea, Republic of, Poland, Russian Federation, Taiwan, France, Turkey, Japan, Italy, United Kingdom, Puerto Rico
Celgene

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

Eosinophilic Esophagitis

Australia, United States, Argentina, Austria, Belgium, Canada, Germany, Israel, Italy, Japan, Poland, Portugal, Spain, Switzerland, United Kingdom
Celgene

Completed

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

Multiple Sclerosis | Multiple Sclerosis, Relapsing-Remitting

United States, Germany
BeiGene

Terminated

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

China, Taiwan, Australia, United States
BeiGene

Active, not recruiting

Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer

Colorectal Cancer

China
Celgene

Terminated

Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma

Lymphoma, Large B-Cell, Diffuse

United States, France, Canada, Italy
Celgene

Completed

Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD)

Lymphoma, Non-Hodgkin

Italy, Switzerland, Austria, Belgium, France, Germany, Japan, Netherlands, Spain, United Kingdom, Finland
BeiGene

Active, not recruiting

To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors

Advanced Solid Tumor

China
BeiGene

Completed

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)

Spain, United States, United Kingdom, China, Taiwan, Korea, Republic of, Japan, France, Germany, Belgium, Italy
Celgene

Active, not recruiting

Connect® MM- The Multiple Myeloma Disease Registry

Multiple Myeloma

United States, Puerto Rico
Celgene

Completed

Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Lymphoma | Lymphoma, Large B-Cell, Diffuse | Glioblastoma | Multiple Myeloma | Primary Central Nervous System Lymphoma | Pleiotropic Pathway Modifier

United States, Spain, Belgium, France, Italy
Celgene

Completed

ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma

Lymphoma, T-Cell, Peripheral

Japan
Celgene

Terminated

Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease

Systemic Sclerosis | Scleroderma, Systemic | Systemic Scleroderma | Interstitial Lung Disease | Sclerosis, Systemic

United States, Spain, France, Australia, Italy, Switzerland, Germany, Poland, United Kingdom, Russian Federation
BeiGene

Completed

Study Investigating Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activities of Anti-PD-1 (Programmed Death-1) Monoclonal Antibody

Advanced Solid Tumors

China
Celgene

Active, not recruiting

Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice

Multiple Myeloma

Austria
BeiGene

Active, not recruiting

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, China, Taiwan, Belgium, France, United Kingdom, Spain, New Zealand, Australia, Czechia, Italy, Poland, Russian Federation, Sweden, Austria
Celgene

Active, not recruiting

Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (KarMMa-7)

Multiple Myeloma

United States, Spain
BeiGene

Completed

AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

Cervical Cancer

Korea, Republic of, Taiwan, China, Thailand, Poland, Bulgaria, Russian Federation, Ukraine
Celgene

Active, not recruiting

Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma

Multiple Myeloma

United States, France, Spain, Germany, Greece
Celgene

Active, not recruiting

A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas

Lymphoma

United States, France, Germany, Italy, Korea, Republic of, Taiwan
BeiGene

Active, not recruiting

Ociperlimab With Tislelizumab and Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer, Stage IV | Locally Advanced, Unresectable, or Metastatic Nonsmall Cell Lung Cancer (NSCLC)

United States, China, Korea, Republic of, France, Spain, Australia, Austria
Celgene

Completed

Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants

Healthy Volunteers

United States
Celgene

Completed

A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence

Primary Myelofibrosis | Anemia

United States, France, Italy, United Kingdom
Celgene

Completed

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)

Multiple Myeloma

United States
BeiGene

Active, not recruiting

Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent or Metastatic Nasopharyngeal Cancer

China, Taiwan, Thailand
Celgene

Terminated

Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.

Beta Thalassemia Intermedia | Beta Thalassemia Major

France, United Kingdom, Italy, Greece
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Belgium, Germany, Spain, Canada, Serbia, Colombia, Poland, Argentina, Brazil, Mexico, Hungary, France, Russian Federation, Italy
BeiGene

Active, not recruiting

Study of Platinum Plus Etoposide With or Without BGB-A317 in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Small Cell Lung Cancer

China
BeiGene

Completed

Study to Investigate the Effect of Rifampin and Itraconazole on the Action of Pamiparib in Participants With Cancer

Solid Tumor

Georgia, Moldova, Republic of, Poland, Slovakia
Celgene

Completed

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

United States, Austria, United Kingdom, Estonia, Denmark
Celgene

Active, not recruiting

A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma

Glioblastoma

Spain, United States, Denmark, Italy, Netherlands, Norway, Sweden
Celgene

Terminated

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

Leukemia, Myeloid

United States, France, Belgium, Spain
Celgene

Completed

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Canada, Spain, United Kingdom, United States, France, Austria, Germany, Italy, Netherlands, Belgium, Portugal, Poland
Celgene

Terminated

A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

Carcinoma, Squamous Cell

United States
Celgene

Completed

Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal) (POM Renal)

Multiple Myeloma | Renal Impairment

United States, Canada

3

Subscribe